Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica

David F.L. Liew,Sarah L. Mackie,Alice Tison,Sebastian E. Sattui,Max Yates,Russell R.C. Buchanan,Claire E. Owen

DOI: https://doi.org/10.1016/j.rdc.2024.02.001

IF: 2.032

2024-04-26

Rheumatic Disease Clinics of North America

Abstract:• Polymyalgia rheumatica (PMR) immune-related adverse events (ICI-PMR) are a distinct entity with many clinical, laboratory, and imaging similarities to classical PMR. • ICI-PMR must be differentiated from other immune-related adverse events including inflammatory arthritis, as well as classical PMR mimics. • Current ICI-PMR therapy is based on classical PMR treatment approaches, although immuno-oncological considerations must be incorporated through shared decision-making between patient and clinician. Polymyalgia rheumatica (PMR) immune-related adverse events (ICI-PMR) are a distinct entity with many clinical, laboratory, and imaging similarities to classical PMR. ICI-PMR must be differentiated from other immune-related adverse events including inflammatory arthritis, as well as classical PMR mimics. Current ICI-PMR therapy is based on classical PMR treatment approaches, although immuno-oncological considerations must be incorporated through shared decision-making between patient and clinician.

rheumatology